Разработка методики определения оптимального размещения устройств симметрирования для систем электроснабжения 0,4 кВ с электродвигательной нагрузкой

In this paper, we consider the development of methods for determining the optimal location of symmetrization devices for 0.4 kV power supply systems with motor-actuated load. The methodology includes the features of electric consumers and their geographical location. The practice procedures for application of the existing power supply system the Taptugary village, the Mogochinsk region, the Trans-Baikal Territory was given as an example. The practical significance for the developed application procedures was justified. The optimal solution of balancing problem based on economical parameters was obtainedРассматриваются вопросы разработки методики определения оптимального размещения устройств симметрирования для систем электроснабжения 0,4 кВ с электродвигательной нагрузкой. В методику заложены особенности электропотребителей и их географическое расположение. Приведен пример применения методики для существующей системы электроснабжения с. Таптугары Могочинского района Забайкальского края. Дано обоснование практической значимости применения разработанной методики. Получено оптимальное решение вопроса симметрирования исходя из экономических показателе

Разработка методики определения оптимального размещения устройств симметрирования для систем электроснабжения 0,4 кВ с электродвигательной нагрузкой

In this paper, we consider the development of methods for determining the optimal location of symmetrization devices for 0.4 kV power supply systems with motor-actuated load. The methodology includes the features of electric consumers and their geographical location. The practice procedures for application of the existing power supply system the Taptugary village, the Mogochinsk region, the Trans-Baikal Territory was given as an example. The practical significance for the developed application procedures was justified. The optimal solution of balancing problem based on economical parameters was obtainedРассматриваются вопросы разработки методики определения оптимального размещения устройств симметрирования для систем электроснабжения 0,4 кВ с электродвигательной нагрузкой. В методику заложены особенности электропотребителей и их географическое расположение. Приведен пример применения методики для существующей системы электроснабжения с. Таптугары Могочинского района Забайкальского края. Дано обоснование практической значимости применения разработанной методики. Получено оптимальное решение вопроса симметрирования исходя из экономических показателе

Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection

We are developing an associated vaccine based on live influenza vaccine (LAIV) and streptococcal recombinant peptides. The recombinant group B streptococcus (GBS) peptides P6 and ScaAB demonstrated a distinguished immunomodulating effect in THP-1 cells. The increase in IFN 1-alpha expression after ScaAB inoculation was similar to that against LAIV. We immunized mice intranasal using of A/H7N3 LAIV or/and ScaAB peptide. At day 5 after immunization, we detected serum IgM which reacted with non-vaccine influenza viruses. Associated vaccination of mice using LAIV and GBS peptide was the most effective against sub-lethal infection with A/H7N9 influenza virus and against lethal challenge with A/H1N1pdm virus at day 5 after immunization. Not only LAIV but also the ScaAB protected about 20% of the immunized animals against lethal challenge with A/H1N1pdm virus. The early protection was related to increasing type 1 interferons expression in the lungs.Our results in mice have shown that successful protection against homologous and heterologous influenza infections can be achieved soon after vaccination with either LAIV or LAIV in combination with GBS recombinant peptide. Presumably, such protection may be mediated by non-specific IgM antibodies and an increase in the expression of early cytokines in the airway

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma.

Background Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. Methods We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. Results Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. Conclusions In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391 .)